Milan, Italy

Roberto Caponi

This inventor holds 1 USPTO granted patent. Top assignee: Istituto Biochimico Italiano Giovanni Lorenzini S.p.a.. Active years: 1993.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1993

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Roberto Caponi

Introduction

Roberto Caponi is a notable inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on inclusion complexes. His research focuses on enhancing the bioavailability of Silybinin, a compound with potential therapeutic applications.

Latest Patents

Roberto Caponi holds a patent for "Inclusion complexes with silybinin, their preparation and pharmaceutical applications." This invention relates to the creation of inclusion complexes of Silybinin with cyclodextrins, including alpha, beta, and gamma-cyclodextrin, as well as suitable derivatives. The inclusion complexes developed by Caponi demonstrate a highly improved bioavailability compared to Silybinin alone, making them particularly valuable in treating various hepatotoxic conditions.

Career Highlights

Caponi is associated with Istituto Biochimico Italiano Giovanni Lorenzini S.p.a., where he has been able to apply his expertise in biochemistry and pharmaceuticals. His work has contributed to advancements in drug formulation and delivery systems.

Collaborations

Throughout his career, Roberto Caponi has collaborated with esteemed colleagues such as Enrico Bosone and Umberto Valcavi. These partnerships have fostered a collaborative environment that enhances research and innovation in the pharmaceutical sector.

Conclusion

Roberto Caponi's contributions to the field of pharmaceuticals through his innovative patent on Silybinin inclusion complexes highlight his role as a significant inventor. His work not only advances scientific knowledge but also has the potential to improve treatment options for patients with hepatotoxic conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…